Claimed effect · Amycretin

Does Amycretin help with body weight?

C
Grade C — weak human evidence1 phase 1b/2a RCT (n=125) · effect size: large
Short answerWeak human evidence. 1 phase 1b/2a RCT (n=125): enough to be interesting, not enough to count on. Where an effect is seen it is a large effect. Doses were escalated over 20–36 weeks. At the top 60 mg dose, weight fell 24.3% against 1.1% on placebo. Substantial numbers of participants withdrew, mostly for reasons unrelated to side effects, which limits how much weight the figure carries.

What the studies show

Doses were escalated over 20–36 weeks. At the top 60 mg dose, weight fell 24.3% against 1.1% on placebo. Substantial numbers of participants withdrew, mostly for reasons unrelated to side effects, which limits how much weight the figure carries.

“Estimated mean bodyweight change from baseline was significantly (Parts A-D: p<0·0001; Part E: p=0·0003) higher with amycretin versus placebo in Part B (60 mg, -24·3% vs -1·1%; week 36), Part C (20 mg, -22·0% vs 1·9%; week 36), Part D (5 mg, -16·2% vs 2·3%; week 28), and Part E (1·25 mg, -9·7% vs 2·0%; week 20).”

Verbatim, from the abstractDahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 2025;406:149–162

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1

In context

Amycretin is a single molecule that activates both the GLP-1 and the amylin receptor, combining the two mechanisms that CagriSema delivers as two drugs. Its international name is now zenagamtide. In the first published trial — a phase 1b/2a study in 125 people — the highest dose produced 24.3% weight loss at 36 weeks: the largest figure reported for any weight-loss drug at this stage, from a small, early trial in which many participants withdrew. Two phase 2 trials in type 2 diabetes, published in The Lancet in 2026, add a dose-dependent HbA1c reduction of up to 1.7 points; the weight-loss figure has not yet been repeated in a larger trial.

Amycretin is investigational (early phase). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Amycretin proven to help with body weight?
No. The human evidence is weak (1 phase 1b/2a RCT (n=125)); LYO grades it C.
What studies are behind the grade?
Doses were escalated over 20–36 weeks. At the top 60 mg dose, weight fell 24.3% against 1.1% on placebo. Substantial numbers of participants withdrew, mostly for reasons unrelated to side effects, which limits how much weight the figure carries.
Is Amycretin approved for this?
No. Amycretin is investigational (early phase); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Amycretin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →